Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology
Portfolio Pulse from
Intelligent Bio Solutions Inc. has submitted a 510(k) premarket notification to the US FDA for its Fingerprint Sweat-Based Drug Screening Technology, aiming for US market entry in 2025.
December 18, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intelligent Bio Solutions Inc. has submitted a 510(k) premarket notification to the FDA for its Fingerprint Drug Screening System, marking a significant step towards US market entry in 2025.
The submission of a 510(k) premarket notification to the FDA is a crucial step for INBS to enter the US market with its drug screening technology. Successful clearance could lead to increased market opportunities and revenue growth, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100